Bank skeptical about Novo Nordisk share price – requires USD 40bn a year in obesity drug sales
Berenberg is baffled by Novo Nordisk's share price, which according to the Germany-based bank, would require an almost impossible sales volume for obesity drug Wegovy.
BY ULRICH QUISTGAARD, TRANSLATED BY CATHERINE BRETT
A new analysis conducted by German bank Berenberg has left it with questions about Novo Nordisk's share price, which currently reflects a market expectation that its obesity drug Wegovy will acheive peak sales of USD 40bn (DKK 250bn) a year.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
.jpg)
